News
-
09.02.2010
Debiopharm Group™ grants an exclusive licence for the development, manufacture and commercialisation of Debio 025 - A potent, first-in-class antiviral agent for the treatment of Hepatitis C - -
04.02.2010
Launch of Ipsen’s Decapeptyl® 6-month formulation (LP 22.5 mg) in France for the treatment of locally advanced or metastatic hormone-dependent prostate cancer
| The JCA Mauvernay Award / Japan |
|
In 2009, Debiopharm Group and the Japanese Cancer Association (JCA) honored Dr Toshikazu Ushijima, National Cancer Center Research Institute, Tokyo with the JCA Mauvernay Award for outstanding work in oncology. The JCA Mauvernay Award was granted on October 3, 2009, at the occasion of the 68th Annual Meeting of the Japanese Cancer Association held from October 1 until October 3 in Yokohama, Japan. Professor Setsuo Hirohashi, President of the JCA and Dr Rolland-Yves Mauvernay, Founder and President of Debiopharm Group presented the award. The Award, funded by Debiopharm and organised by the JCA, aims to recognise cutting-edge oncology research in both the fundamental and the clinical aspects and to encourage Japanese researchers to make their work available to other parts of the world. Potential Candidates must be researchers and members of the JCA who have been recommended by the councillors of the JCA and who have achieved excellent results in the fields of either basic or clinical research in oncology. The JCA counts about 17,000 members, all from universities, governmental and private research organisations throughout Japan. Each year, the Award Committee selects nominee(s) for the JCA-Mauvernay Award from fundamental cancer research and/or clinical cancer research. Nominees:2009
2008
Japanese Cancer Association and Debiopharm Honour Japanese Research - Professors Ichijo and Mano receive 2008 JCA-Mauvernay Award 2007
Japanese Scientists Receive JCA-Mauvernay Award 2007 2006
2005
|



